Journal of hepato-biliary-pancreatic sciences · 2026
Middle Pancreatectomy for Low-Grade Malignancies: Superior Long-Term Glucose Tolerance Preservation Over Distal Pancreatectomy.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fujinaga Atsuro, Esaki Minoru, Kitamura Kei, Umino Ryosuke, Mizui Takahiro, Miyata Akinori, Nara Satoshi
Аннотация
BACKGROUND: This study compared outcomes of middle pancreatectomy (MP) and distal pancreatectomy (DP), focusing on long-term glucose tolerance.
METHODS: We retrospectively reviewed 282 patients who underwent MP (n = 69) or DP (n = 213) for low-grade malignant tumors from 2000 to 2020. Surgical outcomes, HbA1c levels, prevalence of diabetes mellitus (DM), and escalation of antidiabetic medication were analyzed.
RESULTS: MP was associated with longer operation time (312 vs. 245 min, p < 0.001) and higher pancreatic fistula rate (64% vs. 47%, p = 0.018). Among 248 patients with 3-year follow-up, MP showed lower HbA1c levels (5.9% vs. 6.3%, p < 0.001), lower incidence of new-onset DM (3% vs. 30%, p < 0.001), and fewer cases of increased antidiabetic medication use (8% vs. 24%, p = 0.005). Insulin therapy was newly required in 1 MP case versus 18 DP cases.
CONCLUSION: Despite higher morbidity, MP demonstrated superior preservation of long-term glucose tolerance compared with DP. These findings suggest that MP is a valuable parenchyma-preserving option for patients with low-grade malignant pancreatic tumors, particularly those at increased risk of postoperative DM, although careful consideration of surgical risks is required.
METHODS: We retrospectively reviewed 282 patients who underwent MP (n = 69) or DP (n = 213) for low-grade malignant tumors from 2000 to 2020. Surgical outcomes, HbA1c levels, prevalence of diabetes mellitus (DM), and escalation of antidiabetic medication were analyzed.
RESULTS: MP was associated with longer operation time (312 vs. 245 min, p < 0.001) and higher pancreatic fistula rate (64% vs. 47%, p = 0.018). Among 248 patients with 3-year follow-up, MP showed lower HbA1c levels (5.9% vs. 6.3%, p < 0.001), lower incidence of new-onset DM (3% vs. 30%, p < 0.001), and fewer cases of increased antidiabetic medication use (8% vs. 24%, p = 0.005). Insulin therapy was newly required in 1 MP case versus 18 DP cases.
CONCLUSION: Despite higher morbidity, MP demonstrated superior preservation of long-term glucose tolerance compared with DP. These findings suggest that MP is a valuable parenchyma-preserving option for patients with low-grade malignant pancreatic tumors, particularly those at increased risk of postoperative DM, although careful consideration of surgical risks is required.